Jared N Cumming

USPTO Granted Patents = 79 (Patent Applications = 10)

CIPO Patents = 3 (Patent Applications = 8)

EPO Patents = 43 (Patent Applications = 34)

Average Co-Inventor Count = 6.4

ph-index = 9

Forward Citations = 317(Granted Patents)

Inventors with similar research interests:

Location History:

Kenilworth, NJ (US) (2013)
Garwood, NJ (US) (2009 - 2019)
Winchester, MA (US) (2018 - 2024)

Company Filing History:

69 out of 2,405

Merck Sharp + Dohme Corp.

Pharmacopeia Drug Discovery, Inc.

The Walter and Eliza Hall Institute of Medical Research

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

79 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

2. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

3. 12263171 - 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2025-04-01),

4. 12240867 - Arginase inhibitors and methods of use (2025-03-04),

5. 12215116 - Arginase inhibitors and methods of use (2025-02-04),

6. 12060357 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2024-08-13),

7. 11766435 - N3-substituted iminopyrimidinones as antimalarial agents (2023-09-26),

8. 11702430 - Aza-benzothiophene compounds as STING agonists (2023-07-18),

9. 11685761 - Cyclic di-nucleotide compounds as sting agonists (2023-06-27),

10. 11466047 - Cyclic di-nucleotide compounds as sting agonists (2022-10-11),

11. 11453697 - Cyclic di-nucleotide compounds as sting agonists (2022-09-27),

12. 11312772 - Combinations of PD-1 antagonists and benzo [b] thiophene STING agonists for cancer treatment (2022-04-26),

13. 11312719 - 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use (2022-04-26),

14. 11285131 - Benzo[b]thiophene STING agonists for cancer treatment (2022-03-29),

15. 11274111 - Arginase inhibitors and methods of use (2022-03-15),

Title: The Innovative Contributions of Jared N. Cumming

Introduction

Jared N. Cumming, based in Garwood, NJ, is a prolific inventor with an impressive portfolio of 75 patents. His work primarily focuses on biopharmaceuticals, specifically in the development of compounds that serve as therapeutic agents in treating various diseases. With a strong background in the pharmaceutical industry, he has made significant strides in innovation, enhancing treatment options for patients.

Latest Patents

Among his latest contributions are groundbreaking inventions such as arginase inhibitors and methods of use. These inventions involve compounds designated as Formula I, which act as arginase inhibitors, potentially offering new avenues for preventing and treating arginase-related diseases. Additionally, he has patented 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists. This invention describes pharmaceutical compositions that utilize these compounds to treat a variety of disorders mediated by adenosine receptors, showcasing Cumming's dedication to advancing medical science.

Career Highlights

Cumming's career encompasses notable positions at major pharmaceutical companies, including Merck Sharp & Dohme Corporation and Schering Corporation. His experience in these firms has granted him the opportunity to hone his skills in drug development and innovation, ultimately leading to the creation of his significant patent portfolio.

Collaborations

Throughout his career, Jared N. Cumming has collaborated with distinguished professionals like Andrew William Stamford and Ulrich Iserloh. These collaborations have fostered an environment of innovation, resulting in pioneering pharmaceuticals that address critical health issues.

Conclusion

Jared N. Cumming’s extensive patent portfolio and career achievements highlight his impact on the pharmaceutical industry. With continued dedication to innovation, he remains a prominent figure in the field, contributing to advancements that aim to improve therapeutic options for patients worldwide. His work exemplifies the crucial relationship between invention and healthcare, showcasing how innovations can lead to better health outcomes.

This text is generated by artificial intelligence and may not be accurate.